Mounjaro UK
Mounjaro UK The Complete Plain English Guide
The plain English UK guide to Mounjaro. How tirzepatide works, what the trials show, side effects, NHS access, private treatment and what UK patients need to know before starting.
What is Mounjaro?
Mounjaro is the UK brand name for tirzepatide, a prescription-only medicine developed by Eli Lilly. It is given once a week by injection and is authorised in the UK for type 2 diabetes and for weight management in eligible adults.
For weight management, the UK marketing authorisation covers adults with obesity, or adults who are overweight and have at least one weight-related health problem, alongside a reduced-calorie diet and increased physical activity. NHS access is narrower than the medicine’s licence and is being introduced in phases in England.
Mounjaro comes as a pre-filled KwikPen. It is injected under the skin of the abdomen, thigh or upper arm. The usual starting dose is 2.5mg once weekly for four weeks, then 5mg once weekly. If needed and tolerated, the dose can be increased in 2.5mg steps after at least four weeks on the current dose, up to 15mg once weekly.
How does tirzepatide work?
Tirzepatide is a dual GIP and GLP-1 receptor agonist. These are hormone pathways involved in blood glucose regulation, appetite and energy intake. Tirzepatide also delays gastric emptying, particularly after starting treatment and during dose escalation.
The practical effect for many people is reduced hunger, earlier fullness and lower food intake. The strength of that effect varies between individuals and across doses.
Semaglutide, the active ingredient in Ozempic and Wegovy, acts on the GLP-1 receptor rather than both GIP and GLP-1. Importantly, we now have a direct obesity trial rather than relying only on separate studies: in SURMOUNT-5, tirzepatide produced 20.2 percent average weight loss at 72 weeks compared with 13.7 percent with semaglutide at the maximum tolerated doses used in the trial. That head-to-head result applies to the specific population and doses studied; it does not mean every person will lose more weight on Mounjaro.
Mounjaro vs Ozempic vs Wegovy – the honest comparison
Ozempic and Wegovy both contain semaglutide, but they are different products with different UK indications and dosing. Ozempic is authorised for type 2 diabetes; it is not the UK semaglutide product licensed for weight management. Wegovy is authorised for weight management in eligible adults.
The standard Wegovy injection uses semaglutide up to 2.4mg weekly. In January 2026, the MHRA also authorised a maximum 7.2mg weekly dose for adults with obesity only. The 7.2mg regimen is administered as three 2.4mg injections and does not apply to people with a BMI below 30 using Wegovy for weight management or to the cardiovascular-risk indication. The STEP UP trial reported 20.7 percent average weight loss at 72 weeks under its efficacy estimand for semaglutide 7.2mg.
For Mounjaro, SURMOUNT-1 reported 20.9 percent average weight loss at 72 weeks with tirzepatide 15mg under the treatment-regimen estimand, or 22.5 percent under the efficacy estimand. More recently, the direct SURMOUNT-5 trial found 20.2 percent with tirzepatide versus 13.7 percent with semaglutide 1.7mg or 2.4mg at 72 weeks in adults with obesity without diabetes.
Those figures should not be mixed into a simple league table: STEP UP and SURMOUNT-5 used different populations, doses and statistical approaches. For the broader evidence, including adverse-event discontinuation, quality of life and cardiovascular outcomes, see our weight loss jabs and pills compared guide.
What did the SURPASS trials actually show?
The SURMOUNT programme established tirzepatide’s effectiveness for weight management. SURMOUNT-1 enrolled 2,539 adults with obesity, or overweight plus at least one weight-related complication, without diabetes. Participants received tirzepatide 5mg, 10mg or 15mg once weekly, or placebo, for 72 weeks.
The primary published results used the treatment-regimen estimand, which includes participants regardless of treatment discontinuation. Average weight loss was 15.0 percent with 5mg, 19.5 percent with 10mg and 20.9 percent with 15mg, compared with 3.1 percent with placebo. Under the efficacy estimand, which estimates the effect if treatment was taken as intended, the corresponding figures were 16.0, 21.4 and 22.5 percent.
At 15mg, 57 percent of participants lost at least 20 percent of their starting weight under the treatment-regimen estimand. Thirty-six percent achieved at least 25 percent weight loss in the trial’s exploratory analysis. The original paper did not establish 30 percent weight loss as a formal ‘bariatric surgery threshold’, so we do not use that description here.
SURMOUNT-5 later provided the direct comparison many people wanted. Among 751 adults with obesity without diabetes, maximum tolerated tirzepatide produced 20.2 percent average weight loss at 72 weeks compared with 13.7 percent for maximum tolerated semaglutide 1.7mg or 2.4mg.
These are group averages from controlled trials, not a prediction for an individual. Starting weight, dose reached, treatment duration, tolerability, health conditions and adherence all affect outcomes.
Side effects – the full honest picture
The most common Mounjaro side effects are gastrointestinal. Nausea, diarrhoea, vomiting, abdominal pain and constipation are all listed in the UK product information, and symptoms are particularly common while the dose is being increased. They are often mild to moderate, but some people do need to pause dose escalation, reduce the dose with clinical advice or stop treatment.
There is no evidence-based rule that everyone should inject in the evening. The UK product information says Mounjaro can be taken at any time of day, with or without meals. If gastrointestinal symptoms are troublesome, smaller meals and avoiding foods that clearly trigger symptoms may help, but persistent or severe symptoms should be discussed with the prescriber rather than simply pushed through.
In SURMOUNT-1, adverse events led to treatment discontinuation in 4.3 percent of participants on 5mg, 7.1 percent on 10mg and 6.2 percent on 15mg, compared with 2.6 percent on placebo.
Acute pancreatitis is an important but uncommon risk. In January 2026, the MHRA strengthened warnings across GLP-1 and dual GIP/GLP-1 medicines after reports that included necrotising and fatal pancreatitis. Persistent, severe abdominal pain, which may radiate to the back and may occur with nausea or vomiting, needs urgent medical assessment. If pancreatitis is suspected, tirzepatide should be stopped; if confirmed, it should not be restarted.
The risk of hypoglycaemia is higher when tirzepatide is used with insulin or a sulfonylurea, so doses of those medicines may need review. Tirzepatide also delays gastric emptying and can affect the absorption of some oral medicines during dose escalation.
Mounjaro itself is not a condition that must automatically be reported to the DVLA. However, you must not drive if treatment or a medical condition makes you unsafe to drive. DVLA says sudden, disabling or recurrent dizziness must be reported. The often-quoted £1,000 fine relates to failing to tell DVLA about a notifiable medical condition, not simply to taking Mounjaro.
Hair loss is listed as a common adverse reaction in people using tirzepatide for weight management. Rapid weight loss itself can also contribute to temporary hair shedding, so persistent or marked hair loss is worth discussing with a clinician.
How to get Mounjaro on the NHS
NHS access to Mounjaro for weight management in England is being introduced in phases, so the criteria for the medicine’s licence, NICE eligibility and current primary-care rollout are not all the same.
NICE recommends tirzepatide as an option for adults with an initial BMI of at least 35 and at least one weight-related comorbidity, alongside a reduced-calorie diet and increased physical activity. The BMI threshold is usually reduced by 2.5 for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds.
NHS England’s current primary-care rollout is narrower. As of September 2026, people may be eligible in primary care if they have a BMI of at least 35, adjusted for ethnicity, and four of five specified conditions: hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease and type 2 diabetes. This expanded from the initial BMI 40-plus cohort from around June 2026.
Specialist weight-management services operate separately and can prescribe tirzepatide where a specialist considers it appropriate under the commissioned pathway. Access, referral arrangements and service capacity can vary locally, so meeting the broad NICE criteria does not necessarily mean a GP can prescribe immediately.
If you think you may qualify, ask your GP or local service about the current tirzepatide pathway in your area. In England, normal NHS prescription-charge rules apply unless you are exempt or covered by a valid prepayment certificate; an NHS Mounjaro prescription is not automatically free simply because you meet the clinical criteria.
How to get Mounjaro privately
Private Mounjaro is available through regulated UK pharmacies and prescribing services. Because tirzepatide is prescription-only, a legitimate provider should carry out an appropriate clinical assessment before supplying it and provide a route for follow-up and safety advice.
For pharmacies in Great Britain, check the dispensing pharmacy on the General Pharmaceutical Council register. If a separate online doctor or healthcare service is providing the clinical consultation in England, you can also check whether that service appears on the Care Quality Commission register where applicable. Northern Ireland uses a different pharmacy regulator.
Be cautious of sellers offering prescription weight-loss medicines without a proper assessment, through social media, or from an unregulated website. The MHRA says genuine GLP-1 medicines should be obtained from a legitimate pharmacy with a prescription from a healthcare professional.
This is not a theoretical risk. In February 2026 the MHRA reported falsified Mounjaro 15mg KwikPens supplied through one UK online pharmacy, and in May it announced its largest ever seizure of unlicensed weight-loss medicines, including illicit tirzepatide.
Our UK Clinic Reviews section looks at individual providers, while our live price comparison tracks current advertised treatment costs. Provider inclusion on this site is not a substitute for checking the relevant regulator and completing an individual medical assessment.
What does Mounjaro cost in the UK?
For NHS treatment in England, normal prescription-charge rules apply unless you are exempt or use a valid prepayment certificate.
Private prices vary substantially by provider and dose and can change quickly. Rather than fixing a price on this evergreen guide, see our independent Mounjaro price comparison for the latest prices we have checked across major UK providers.
When comparing offers, check what the quoted price includes: the prescribed dose, consultation or follow-up, delivery and any membership charge. A low headline price can be misleading if it applies only to a first order or introductory offer.
Price should not be used as the only legitimacy check. The MHRA has documented both illegal weight-loss medicines and falsified Mounjaro pens in the UK, so always verify the pharmacy and prescription process as well.
What happens when you stop Mounjaro?
Weight regain after stopping tirzepatide is common, but the exact amount varies.
SURMOUNT-4 gives the clearest controlled evidence. All participants first received tirzepatide for 36 weeks and lost an average 20.9 percent of their starting weight. They were then randomised either to continue tirzepatide or switch to placebo for another 52 weeks. From week 36 to week 88, the placebo group regained 14.0 percent of their body weight, while those who continued tirzepatide lost a further 5.5 percent. At week 88, 16.6 percent of those switched to placebo had maintained at least 80 percent of their initial weight loss, compared with 89.5 percent of those who continued tirzepatide.
That does not mean everybody regains the same proportion or on the same timetable. Obesity is a chronic, relapsing condition and appetite regulation changes again when treatment is withdrawn. Diet, activity, support, starting weight and individual biology all matter.
The practical point is to discuss the expected duration of treatment and a plan for maintaining weight loss before stopping. NICE explicitly warns that stopping tirzepatide without continuing a reduced-calorie diet and increased physical activity is likely to lead to weight regain.
Maintaining weight loss long term
Mounjaro is licensed to be used alongside a reduced-calorie diet and increased physical activity. NICE advises discussing treatment duration and weight-maintenance planning from the start, because treatment may be long term if it continues to provide benefit.
If someone loses weight and later chooses to stop tirzepatide, NICE recommends continuing support with diet and physical activity to help maintain the loss. If weight is regained after stopping, NICE says clinicians can consider a higher level of lifestyle support, with or without restarting tirzepatide, depending on the individual situation.
There is no general NICE or UK product-information rule saying Mounjaro must be gradually tapered before stopping. The previous version of this page overstated that point. Dose reduction can be useful when managing adverse effects during titration, but decisions to stop, reduce or restart should be made with the prescriber rather than following an unsupervised tapering schedule.
NICE also recommends reviewing response: if less than 5 percent of initial weight has been lost after six months on the highest tolerated dose, the benefits and risks of continuing should be reconsidered.
Swipe sideways to see the full table →
|
Treatment |
Average Weight Loss |
Receptors Targeted |
UK Status |
Live Pricing |
|---|---|---|---|---|
|
Retatrutide |
28.3% |
3 (GLP-1 GIP Glucagon) |
Not approved |
Coming soon |
|
Mounjaro |
20.9% at 15mg* |
2 (GLP-1 GIP) |
Approved |
|
|
Wegovy (injection) |
14.9% (2.4mg); 20.7% (7.2mg efficacy estimate) |
1 (GLP-1) |
Approved |
|
|
Ozempic |
Not licensed for weight loss |
1 (GLP-1) |
Diabetes only |
Coming soon |
|
CagriSema |
20.4% in REDEFINE 1 |
2 (GLP-1 Amylin) |
Not approved for weight management |
Coming soon |
|
Wegovy Pill |
13.6% in OASIS 4 |
1 (GLP-1) |
Approved in UK |
Coming soon |
Frequently Asked Questions
How much weight will I lose on Mounjaro?
SURMOUNT-1 reported average weight loss of 20.9 percent at 72 weeks with tirzepatide 15mg under the treatment-regimen estimand, or 22.5 percent under the efficacy estimand. Individual results vary and those trial averages are not a prediction for any one person.
Is Mounjaro safe long term?
Mounjaro is authorised in the UK and has been studied in large clinical trials, with safety monitoring continuing after approval. Gastrointestinal effects are the most common. Important risks include acute pancreatitis and hypoglycaemia when used with insulin or sulfonylureas. Long-term treatment should be reviewed with the prescriber according to benefit, side effects and individual health circumstances.
Can I drink alcohol on Mounjaro?
There is no blanket UK prohibition on alcohol while taking Mounjaro. Alcohol can worsen gastrointestinal symptoms and can complicate blood-glucose control, particularly for people using other diabetes medicines. If you have diabetes, pancreatitis risk factors or troublesome side effects, ask your prescriber what is appropriate for you.
Will Mounjaro affect my fertility or pregnancy?
Tirzepatide should not be used during pregnancy and should be stopped at least one month before a planned pregnancy. For people with overweight or obesity using an oral contraceptive, UK product information advises switching to a non-oral method or adding a barrier method for four weeks after starting tirzepatide and for four weeks after each dose increase because reduced oral-contraceptive effectiveness cannot be excluded.
Can I exercise on Mounjaro?
Yes. Mounjaro for weight management is licensed for use alongside a reduced-calorie diet and increased physical activity. The right type and intensity of exercise depends on your health, fitness and any medical conditions, so people who have been inactive or have significant health problems may need individual advice.
What is the difference between Mounjaro and retatrutide?
Mounjaro contains tirzepatide and activates GIP and GLP-1 receptors. Retatrutide is an investigational triple agonist that also activates the glucagon receptor. SURMOUNT-1 reported 20.9 percent average weight loss at 72 weeks with tirzepatide 15mg under the treatment-regimen estimand, while Lilly’s later TRIUMPH-1 Phase 3 release reported 28.3 percent at 80 weeks with retatrutide 12mg under an efficacy estimand. These are separate trials and not a head-to-head comparison. Retatrutide is not approved in the UK and no confirmed UK launch date has been announced. Our Retatrutide UK Guide covers the current evidence and regulatory position.
About this page
Page reviewed 16 September 2026. Sources checked include current MHRA product information and safety guidance, NICE TA1026 and tirzepatide prescribing guidance, NHS England’s phased access criteria, SURMOUNT-1, SURMOUNT-4 and SURMOUNT-5. This guide is for information purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, stopping or changing treatment.
Key facts at a glance
Keep reading